Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Leapfrogs Taro With Authorized Generic Epiduo Forte Launch

Israeli Firm Celebrates First-To-Market Launch

Executive Summary

Teva has added another major dermatology brand to its armory, with the launch of an authorized generic version of Galderma’s Epiduo Forte Gel.

You may also be interested in...

Asia Deal Watch: Huadong Licenses Two Cancer ADCs From Heidelberg Pharma

German firm’s antibody-drug conjugates use amanitin payload. Plus deals involving Sanwa Kagaku/Crinetics, Takeda/Code Bio, Taro/Alchemee, Mankind/Dr. Reddy’s and more.

Q4 May Signal If Winlevi Can Give Wings To Sun’s US Specialty Sales

Sun-Cassiopea’s first-in-class topical androgen receptor inhibitor, Winlevi, appears off to an encouraging start in the US, generating prescriptions from 80% of targeted physicians. Can it hold out in the competitive acne therapy segment and add sheen to Sun’s specialty portfolio?

Teva Capitalizes On Patent Expiry To Launch First Perforomist Rival

Teva has added to its vast portfolio in the US by introducing the first generic version of Viatris’ Perforomist for chronic obstructive pulmonary disease, as well as a generic of Soolantra to treat rosacea.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts